APGE · Apogee Therapeutics, Inc.
$134.85
+0.00 (+0.00%)
At close · Aug 26
Going-concern doubt
— cleared Aug 10, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued. ... Based on the Company's current operating plan, it estimates that its existing cash and cash equivalents of $105.6 million, marketable securities of $866.4 million and long-term marketable securities of $321.9 million as of June 30, 2026, will be sufficient to enable the Company to fund its operating expenses and capital requirements through at least the next 12 months from the issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Market Cap
$10.21B
Shares
75.69M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
No Exempt Offerings
No Form D exempt-offering notices are available for this stock yet.
Key facts
CIK
1974640
CUSIP
03770N101
13F (30d)
265 filings
265 filers
Visit website
Investor relations